+

WO2002053700A3 - Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes - Google Patents

Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes Download PDF

Info

Publication number
WO2002053700A3
WO2002053700A3 PCT/US2001/049442 US0149442W WO02053700A3 WO 2002053700 A3 WO2002053700 A3 WO 2002053700A3 US 0149442 W US0149442 W US 0149442W WO 02053700 A3 WO02053700 A3 WO 02053700A3
Authority
WO
WIPO (PCT)
Prior art keywords
epitopes
antibodies
present
isolated molecules
containing sulfated
Prior art date
Application number
PCT/US2001/049442
Other languages
English (en)
Other versions
WO2002053700A2 (fr
Inventor
Janette Lazarovits
Yocheved Hagai
Daniel Plaksin
Tikva Vogel
Abraham Nimrod
Hagit Mar-Haim
Ester Szanthon
Tamar Richter
Boaz Amit
Lena Kooperman
Tuvia Peretz
Avigdor Levanon
Original Assignee
Bio Technology General Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Technology General Corp filed Critical Bio Technology General Corp
Priority to IL15668901A priority Critical patent/IL156689A0/xx
Priority to BRPI0116764-2A priority patent/BR0116764A/pt
Priority to EP01994330A priority patent/EP1406930A4/fr
Priority to CA002433225A priority patent/CA2433225A1/fr
Priority to KR10-2003-7008890A priority patent/KR20030091953A/ko
Priority to MXPA03005945A priority patent/MXPA03005945A/es
Priority to HU0700079A priority patent/HUP0700079A2/hu
Priority to JP2002555211A priority patent/JP2005503756A/ja
Publication of WO2002053700A2 publication Critical patent/WO2002053700A2/fr
Publication of WO2002053700A3 publication Critical patent/WO2002053700A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des épitopes propres aux cellules cancéreuses, qui jouent un rôle important dans certains phénomènes physiologiques comme le roulement cellulaire, la métastase et l'inflammation. L'invention concerne également des procédés et des compositions thérapeutiques et diagnostiques faisant intervenir des anticorps capables de se lier avec les épitopes. Les procédés et les compositions en question peuvent s'appliquer au diagnostic et à la thérapie pour une série de maladies, à savoir par exemple: cancer, y compris la croissance tumorale et la métastase, leucémie, maladie auto-immune, et maladie inflammatoire.
PCT/US2001/049442 2000-12-29 2001-12-31 Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes WO2002053700A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IL15668901A IL156689A0 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
BRPI0116764-2A BR0116764A (pt) 2000-12-29 2001-12-31 moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos
EP01994330A EP1406930A4 (fr) 2000-12-29 2001-12-31 Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
CA002433225A CA2433225A1 (fr) 2000-12-29 2001-12-31 Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
KR10-2003-7008890A KR20030091953A (ko) 2000-12-29 2001-12-31 황산화된 부분을 함유하는 에피토프를 포함하는 분리된분자, 그러한 에피토프에 대한 항체, 및 그들의 용도
MXPA03005945A MXPA03005945A (es) 2000-12-29 2001-12-31 Moleculas aisladas que comprenden epitopes que contienen grupos sulfato, anticuerpos para tales epitopes y usos de ellos.
HU0700079A HUP0700079A2 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
JP2002555211A JP2005503756A (ja) 2000-12-29 2001-12-31 硫酸化部分を含むエピトープを含む単離分子、当該エピトープに対する抗体、及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US25894800P 2000-12-29 2000-12-29
US75118100A 2000-12-29 2000-12-29
US60/258,948 2000-12-29
US09/751,181 2000-12-29

Publications (2)

Publication Number Publication Date
WO2002053700A2 WO2002053700A2 (fr) 2002-07-11
WO2002053700A3 true WO2002053700A3 (fr) 2004-02-12

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/049442 WO2002053700A2 (fr) 2000-12-29 2001-12-31 Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes

Country Status (13)

Country Link
EP (1) EP1406930A4 (fr)
JP (1) JP2005503756A (fr)
KR (1) KR20030091953A (fr)
CN (1) CN100347194C (fr)
BR (1) BR0116764A (fr)
CA (1) CA2433225A1 (fr)
CZ (1) CZ20031982A3 (fr)
HU (1) HUP0700079A2 (fr)
IL (1) IL156689A0 (fr)
MX (1) MXPA03005945A (fr)
PL (1) PL366223A1 (fr)
RU (1) RU2003123101A (fr)
WO (1) WO2002053700A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
JP2005534679A (ja) * 2002-07-01 2005-11-17 サビエント ファーマシューティカルズ，インコーポレイティド 治療的処置のための組成物および方法
CN101300021A (zh) * 2003-06-30 2008-11-05 生物技术通用（以色列）有限公司 抗体及其用途
WO2005005455A2 (fr) * 2003-06-30 2005-01-20 Bio-Technology General (Israel)Ltd. Anticorps humains specifiques
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
MY148646A (en) * 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
KR20130018989A (ko) * 2004-05-11 2013-02-25 압제노믹스 코오페라티에프 유.에이. Ｔ 세포 사멸 유도성 에피토프
AU2010363814B2 (en) 2010-11-12 2016-05-19 Gentium S.R.L. Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD).
NZ619524A (en) 2011-06-13 2016-10-28 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies and uses thereof
CN110079580B (zh) 2012-06-22 2022-12-06 真蒂奥姆责任有限公司 用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
WO2016013828A1 (fr) * 2014-07-21 2016-01-28 연세대학교 산학협력단 Mutant de domaine extracellulaire 1 de récepteur de chimiokines duffy sulfaté et utilisation associée
EP3026122A1 (fr) 2014-11-27 2016-06-01 Gentium S.p.A. Procédé à base cellulaire pour déterminer la puissance de défibrotide
JP2019031486A (ja) * 2017-08-04 2019-02-28 公立大学法人福島県立医科大学 新規ポリペプチド及びその用途
CN109929036B (zh) * 2017-12-19 2024-12-03 泰州迈博太科药业有限公司 一种表位特异的抗体筛选方法及所筛选到的抗体

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011778A1 (fr) * 1991-12-12 1993-06-24 The Scripps Research Institute Molecules anti-thrombotiques bifonctionnelles et polypetptides anti-trhombotiques
KR19990022954A (ko) * 1995-06-14 1999-03-25 어니스트 엠. 해데드 Ｐ-셀렉틴 리간드 및 관련 분자 및 방법
ES2208759T3 (es) * 1995-08-03 2004-06-16 Board Of Regents Of The University Of Oklahoma O-glicanos inhibidores de la inflamacion mediada por selectina.
US5985833A (en) * 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
CA2332563A1 (fr) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptide, technique de synthese et utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SNAPP ET AL.: "A novel P-selectin glycoprotein ligand-1 monoclonal antibody recognizes an epitope within the tyrosine sulfate motif of human PSGL-1 and blocks recognition of both P- and L-selectin", BLOOD, vol. 91, no. 1, 1 January 1998 (1998-01-01), pages 154 - 164, XP002968095 *

Also Published As

Publication number Publication date
JP2005503756A (ja) 2005-02-10
WO2002053700A2 (fr) 2002-07-11
BR0116764A (pt) 2007-01-09
PL366223A1 (en) 2005-01-24
CA2433225A1 (fr) 2002-07-11
CZ20031982A3 (cs) 2004-09-15
RU2003123101A (ru) 2005-03-10
KR20030091953A (ko) 2003-12-03
HUP0700079A2 (en) 2007-05-02
MXPA03005945A (es) 2004-10-15
IL156689A0 (en) 2004-01-04
CN1649900A (zh) 2005-08-03
CN100347194C (zh) 2007-11-07
EP1406930A2 (fr) 2004-04-14
EP1406930A4 (fr) 2007-01-10

Similar Documents

Publication Publication Date Title
WO2002053700A3 (fr) Molecules isolees renfermant des epitopes a fractions sulfatees, anticorps vis-a-vis de ces epitopes, et utilisations correspondantes
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
WO2001096388A3 (fr) Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon
WO2001096390A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2004031411A3 (fr) Genes et polypeptides associes aux cancers du pancreas chez l'homme
WO2000060076A3 (fr) Compositions pour le traitement et le diagnostic du cancer du sein et leurs procedes d'utilisation
WO2002074156A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2001040269A3 (fr) Compositions et methodes destinees au traitement et au diagnostic du cancer du sein
WO2004067023A3 (fr) Peptides derives de la survivine et leur utilisation
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
WO2001000828A3 (fr) Compositions et techniques de therapie et de diagnostic du cancer du poumon
WO2001025272A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2001073032A3 (fr) Compositions et methodes de therapie et de diagnostic du cancer de la prostate
WO2000060077A3 (fr) Composes utilises dans la therapie et le diagnostic du cancer du poumon et methodes d'utilisation
WO2002083070A3 (fr) Composes pour l'ummunotherapie et le diagnostic du cancer du colon et methodes d'utilisation associees
WO2001079286A3 (fr) Compositions et procedes de traitement et de diagnostic du cancer du sein
WO2002092001A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer du poumon
WO2002074237A8 (fr) Compositions et procedes de therapie et de diagnostic du cancer du rein
WO2000037643A3 (fr) Composes destines a l'immunotherapie et au diagnostic du cancer du colon et methodes d'utilisation
WO2002012328A3 (fr) Compositions et methodes utilisees dans la therapie et le diagnostic du cancer du colon
WO2002058534A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du colon
WO2004031231A3 (fr) Genes et polypeptides lies au cancer de la prostate
WO2001073027A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2003037267A8 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
EP1667716B8 (fr) Mise en evidence d'une expression surfacielle du cd44 par la cytotoxicite de cellules

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/005945

Country of ref document: MX

Ref document number: 2433225

Country of ref document: CA

Ref document number: 2002555211

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 156689

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 1020037008890

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200305336

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2003-1982

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 527150

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001994330

Country of ref document: EP

Ref document number: 2002246738

Country of ref document: AU

Ref document number: 01171/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 018228844

Country of ref document: CN

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020037008890

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001994330

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-1982

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: PI0116764

Country of ref document: BR

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载